This is part two of three of the recommendations of seven key opinion leaders on the innovative studies to be presented during EAU18’s Plenary Sessions. Prof. Gert Attard (GB) and Prof. Dr. Thomas Kessler (CH) give a quick overview of Plenary Sessions 3 and 4 respectively.
Prof. Gert Attard (GB)
Plenary Session 3: Prostate Cancer
“Metastatic castration resistant prostate cancer is characterised by aberrations in the androgen receptor that can be detected in circulation and associate with significantly worse outcomes on androgen receptor (AR) targeting drugs but not taxanes. This introduces the opportunity for treatment selection.
Dedicated computational and sequencing approaches can also allow high sensitivity detection and quantitation of copy number aberrations and point mutations in plasma DNA that allow characterization of other molecular types that can improve treatment selection, including aberrations in the DNA repair, PI3K/AKT and WNT pathways. These approaches can allow rational treatment selection in a rapidly changing therapeutic landscape, with treatments moving earlier in the management paradigm. Kessler
Prof. Dr. Thomas Kessler (CH)
Plenary Session 4: Contemporary storage Lower Urinary Tract Symptoms (LUTS) management
Lower Urinary Tract Symptoms (LUTS) are highly prevalent and largely affect the quality of life of neurological patients. Spinal cord injury and spina bifida are generally considered stable neurological diseases, but is this really the case? No, not at all. Modification of the urological management is often necessary over time. Urodynamics is essential in identifying risk factors that jeopardize the upper and lower urinary tract, as well as, guarantee an optimal customised treatment.
In this session, neurological mechanisms involved and consequent urological management strategies will be discussed to improve the outcome for prospective patients with stable neurological diseases.
Continue reading to Part 3.
Hermitage photo courtesy of Daniel Rasmussen